证券代码：688617 证券简称：惠泰医疗 公告编号：2025-009 上述产品后续实际销售情况取决于未来市场的推广效果，公司目前尚无法预 测上述产品对公司未来营业收入的影响，敬请广大投资者理性投资、注意投资风 险。 2025 年 3 月 26 日，深圳惠泰医疗器械股份有限公司（以下简称"公司"） 取得一项医疗器械注册证，具体情况如下： 一、医疗器械注册证的具体情况 | 注册人名称 | 深圳惠泰医疗器械股份有限公司 | | --- | --- | | 产品名称 | 一次性使用磁定位可调弯标测导管 | | 注册分类 | 第三类有源医疗器械 | | 注册证编号 | 国械注准 20253070658 | | 预期用途 | 该产品在医疗机构中与电生理标测设备配合使用，用于心内电生理标 | | | 测、记录和刺激。与上海宏桐实业有限公司生产的三维心脏电生理标测 | | | 系统（型号：HT-9000，软件发布版本：V1）配合使用时还可提供导管 | | | 在心内的位置信息。 | 二、对公司的影响 上述医疗器械注册证的取得，有利于丰富公司的产品种类，扩充公司在电生 理领域产品布局，不断满足多元化的临床需求，进一步增强公司 ...

Investment Rating - The industry investment rating is "Outperform the Market" [3][28] Core Viewpoints - The report emphasizes the potential of AI in healthcare, particularly through the DeepSeek model, which accelerates the implementation of AI in medical settings, enhancing diagnostic efficiency and resource allocation [7][23][27] - The industry is expected to transition from scale expansion to higher-level development, focusing on high-quality growth and long-term investment opportunities [28] Summary by Sections Industry Overview - The medical device sector has shown a monthly increase of 8.67%, outperforming the pharmaceutical sector and the CSI 300 index by 2.26 and 6.04 percentage points respectively [11][15] - The average PE ratio for the medical device sector is 28.93, which is a 9.74% premium over the pharmaceutical sector and a 154.06% premium over the CSI 300 index [15][21] Key Stocks - Major companies highlighted include: - Mindray Medical: EPS of 9.55 in 2023, rated "Buy" [4] - Weili Medical: EPS of 0.66 in 2023, rated "Add" [4] - New Industry: EPS of 2.10 in 2023, rated "Add" [4] - Yuyue Medical: EPS of 2.39 in 2023, rated "Add" [4] - Kefu Medical: EPS of 1.22 in 2023, rated "Add" [4] AI Medical Applications - AI in healthcare is categorized into several applications, including drug development, medical imaging, healthcare robotics, and health management, all aimed at improving service efficiency and quality [25][24] - The report suggests that AI will help address the growing medical demand and resource distribution issues in China, enhancing early disease detection and treatment [24][26] Investment Recommendations - The report recommends focusing on companies with strong innovation capabilities and international expansion potential, such as Mindray Medical, Union Medical, and Weili Medical [28] - It also highlights the importance of AI models like DeepSeek in improving medical efficiency and resource optimization, suggesting attention to companies like BGI and Shengxiang Biological [28]

证券代码：688617 证券简称： 惠泰医疗 公告编号：2025-008 深圳惠泰医疗器械股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 3 月 3 日，深圳惠泰医疗器械股份有限公司（以下简称"公司"）全 资子公司湖南埃普特医疗器械有限公司取得一项医疗器械注册证，具体情况如下： 上述产品后续实际销售情况取决于未来市场的推广效果，公司目前尚无法预 测上述产品对公司未来营业收入的影响，敬请广大投资者理性投资、注意投资风 险。 特此公告。 深圳惠泰医疗器械股份有限公司董事会 2025 年 3 月 5 日 一、医疗器械注册证的具体情况 | 注册人名称 | 湖南埃普特医疗器械有限公司 | | --- | --- | | 产品名称 | 腔静脉滤器系统 | | 注册分类 | 第三类无源医疗器械 | | 注册证编号 | 国械注准 20253130465 | | | 该产品通过经股静脉或经颈静脉入路经皮置入，用于预防下腔静脉系 | | | 统栓子脱落而引起的肺动脉栓塞（PE） ...

该产品通过经股静脉或经颈静脉入路经皮置入，用于预防下腔静脉系统栓子脱落而引起的肺动脉栓塞 （PE）。 人民财讯3月4日电，惠泰医疗(688617)3月4日晚间公告，全资子公司湖南埃普特医疗器械有限公司腔静 脉滤器系统取得医疗器械注册证。 ...

| 1.《电生理业务高速增长，海内外 | | --- | | 业绩持续向好》 2024.09.13 | 公司评级：增持（维持） 近十二个月公司表现 证券研究报告 2025 年 02 月 28 日 湘财证券研究所 公司研究 惠泰医疗（688617.SH）业绩点评 2024 年业绩符合预期，PFA 产品上市有望带来新增量 相关研究： -20% 0% 20% 40% 60% 惠泰医疗 沪深300 | % | 1 个月 | 3 个月 | 12 个月 | | --- | --- | --- | --- | | 相对收益 | -2.7 | 15.5 | 44.1 | | 绝对收益 | -7.9 | 5.1 | 28.7 | 注：相对收益与沪深 300 相比 分析师：聂孟依 证书编号：S0500524040001 Tel：(8621) 50299667 Email：nmy06967@xcsc.com 地址：上海市浦东新区银城路 88 号 中国人寿金融中心 10 楼 核心要点： ❑ 2024 年业绩增长符合预期 报告期内，公司实现营业收入 206,580.16 万元，较上年同期增长 25.18%； 归属于母公司所有者的净利润 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company's performance in 2024 met expectations, with a revenue of 2,065.80 million yuan, a year-on-year increase of 25.18%, and a net profit attributable to the parent company of 673.48 million yuan, up 26.14% year-on-year [4][8] - The company has maintained a net profit growth rate of over 25% for several consecutive years, indicating strong growth potential [4] - The domestic market's product admission rate has continued to improve, with over 150 new hospitals adopting the company's electrophysiology products and a more than 100% increase in the number of three-dimensional electrophysiology surgeries performed [5] - The company is actively expanding its overseas market and enhancing its internal governance structure, focusing on revenue growth, cost control, and quality improvement [6] - Significant R&D progress has been made, with key products approved for market release, including a disposable cardiac pulsed field ablation catheter, which is expected to create new revenue growth opportunities in 2025 [7][8] Financial Summary - The company is projected to achieve revenues of 2,066 million yuan, 2,521 million yuan, and 2,996 million yuan for 2024, 2025, and 2026 respectively, with net profits of 673 million yuan, 922 million yuan, and 1,092 million yuan for the same years [8][11] - The gross profit margin is expected to improve from 72.6% in 2024 to 77.7% in 2026, indicating enhanced profitability [11] - The company's earnings per share (EPS) are forecasted to be 6.92 yuan, 9.47 yuan, and 11.22 yuan for 2024, 2025, and 2026 respectively [11]

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-007 深圳惠泰医疗器械股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 2 月 26 日，深圳惠泰医疗器械股份有限公司（以下简称"公司"） 全资子公司湖南埃普特医疗器械有限公司取得一项医疗器械注册证，具体情况如 下： 一、医疗器械注册证的具体情况 特此公告。 深圳惠泰医疗器械股份有限公司董事会 2025 年 2 月 27 日 | 注册人名称 | 湖南埃普特医疗器械有限公司 | | --- | --- | | 产品名称 | 一次性使用磁定位压力监测射频消融导管 | | 注册分类 | 第三类有源医疗器械 | | 注册证编号 | 国械注准 20253010446 | | 预期用途 | 该产品在医疗机构中使用，与上海宏桐实业有限公司生产的心脏射频消 | | | 融仪（型号：RFG-CF2，软件发布版本 V1）配合使用时，可用于药物 | | | 难治性复发性症状性持续性房颤的治疗。与上海宏桐实业有限公司生 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's 2024 performance report indicates that revenue reached 2.066 billion yuan, reflecting a year-on-year growth of 25.18%, while net profit attributable to shareholders was 673 million yuan, up 26.14% [7] - The launch of the new PFA atrial fibrillation product is expected to create a second growth curve for the company, with significant revenue contributions anticipated in 2025 [7] - The approval of the RescSeal™ thoracic aortic stent in April 2024 is expected to benefit from upcoming centralized procurement in Hebei province, enhancing the market potential for the company's new products [7] Financial Summary - Total revenue projections for 2024-2026 are adjusted to 2.066 billion yuan, 2.762 billion yuan, and 3.594 billion yuan respectively, with corresponding net profits of 673 million yuan, 919 million yuan, and 1.208 billion yuan [7][8] - The company's earnings per share (EPS) are forecasted to be 6.92 yuan in 2024, 9.43 yuan in 2025, and 12.40 yuan in 2026 [1][8] - The price-to-earnings (P/E) ratio is projected to be 54.81 for 2024, 40.17 for 2025, and 30.56 for 2026, indicating a favorable valuation outlook [1][8]

证券研究报告·公司点评报告·医疗器械 惠泰医疗（688617） 2024 年业绩快报点评：业绩符合预期，期待 25 年房颤新品放量 买入（维持） | [Table_EPS] 盈利预测与估值 | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1216 | 1650 | 2066 | 2762 | 3594 | | 同比（%） | 46.74 | 35.71 | 25.18 | 33.70 | 30.12 | | 归母净利润（百万元） | 358.02 | 533.92 | 673.48 | 918.88 | 1,208.00 | | 同比（%） | 72.19 | 49.13 | 26.14 | 36.44 | 31.46 | | EPS-最新摊薄（元/股） | 3.68 | 5.48 | 6.92 | 9.43 | 12.40 | | P/E（现价&最新摊薄） | 103.10 | 69.13 | 54.81 | 40.17 | 30.56 | [Table_Tag] [ ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 2025年2月24日， 惠泰医疗 发布了2024年度业绩快报公告。 # 财务数据 # 经营业绩增长原因 营业收入 ：2024年实现营业总收入20.66亿元，同比增长25.18%。 净利润 ：归属于母公司所有者的净利润为6.73亿元，同比增长26.14%。 扣非净利润 ：归属于母公司所有者的扣除非经常性损益的净利润为6.43亿元，同比增长37.36%。 基本每股收益 ：6.96元，同比增长25.63%。 总资产 ：截至报告期末，公司总资产约为29.76亿元，较期初增长15.65%。 归属于母公司所有者权益 ：约为25.1亿元，较期初增长31.68%。 本次业绩快报数据为初步核算结果，未经会计师事务所审计，最终数据以公司2024年年度报告为准。 报名：首届全球骨科大会 | 奖项评选 该业绩略低于市场一致预期，此前市场预期公司2024年营业总收入为20.83亿至22.91亿元，净利润为6.8亿至8.66亿元。 # 公司介绍 心未来 | 思宇MedTech 首届全球心血管大会 Global Card ...